Group 1 - The UK aims to reduce tariffs on steel, whisky, and pharmaceuticals during Trump's visit, with a focus on finalizing a significant US-UK trade agreement [1] - Trump's previous imposition of a 25% tariff on all imported cars and parts from the UK has led to a temporary halt in shipments from British brands like Aston Martin and Jaguar Land Rover [1] - The US is looking to ensure that only steel processed in the UK qualifies for tariff exemptions, complicating the situation for Tata Steel, which imports steel from its plants in India and the Netherlands [1] Group 2 - The UK seeks a waiver on pharmaceutical tariffs, as major companies like GlaxoSmithKline and AstraZeneca rely heavily on the US market for 42%-52% of their sales [2] - Trump has threatened to impose a 50% tariff on drugs to curb profits of UK pharmaceutical companies, but negotiations are stalled due to the UK's reluctance to lower domestic drug prices [2] - AstraZeneca has announced plans to expand its manufacturing and R&D capabilities in the US, indicating a shift in strategy in response to Trump's tariff policies [2]

Core Viewpoint - HengRui Pharma has entered into a collaboration agreement with GlaxoSmithKline (GSK) to co-develop up to 12 innovative drugs, which will enhance HengRui's globalization efforts and provide GSK with significant growth opportunities post-2031 [1] Group 1: Collaboration Details - The collaboration includes a total upfront payment of $500 million from GSK to HengRui [1][3] - HengRui will license its PDE3/4 inhibitor, HRS-9821, to GSK for global rights outside of Greater China, which is currently in clinical development for chronic obstructive pulmonary disease (COPD) [1][2] - The agreement also encompasses a groundbreaking collaborative plan to develop up to 11 additional projects, with HengRui leading the research and GSK having exclusive options for further development and commercialization [2][3] Group 2: Strategic Implications - The partnership is seen as a significant milestone in HengRui's internationalization process, leveraging GSK's strengths in drug development and global clinical networks to accelerate the entry of innovative therapies into overseas markets [2] - GSK's Chief Scientific Officer emphasized the strategic investment in validated target projects, which can significantly enhance the success rate of research and development [2] - The collaboration aims to integrate GSK's expertise in disease biology and clinical development with HengRui's capabilities in early-stage research and clinical evaluation, maximizing strategic synergies [2] Group 3: Financial Potential - If all projects are successfully developed and milestones are achieved, HengRui could qualify for potential milestone payments totaling approximately $12 billion [3] - HengRui will also be entitled to receive tiered sales royalties from GSK, excluding sales in Greater China [3]

Core Insights - Hengrui Pharma has entered into agreements with GSK to develop up to 12 innovative medicines, enhancing Hengrui's globalization strategy and providing new growth opportunities for GSK beyond 2031 [1][5] - GSK will pay $500 million in upfront fees for the agreements, which include a license for a potential best-in-class PDE3/4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease (COPD) [1][6] Group 1: Agreements and Financials - The agreements grant GSK an exclusive worldwide license for HRS-9821, aimed at treating COPD as an add-on maintenance treatment [2][8] - The total potential value of future success-based payments to Hengrui Pharma could reach approximately $12 billion if all programmes are optioned and milestones achieved [6] Group 2: Development and Collaboration - Hengrui Pharma will lead the development of the additional 11 programmes up to the completion of phase I trials, with GSK having the option to further develop and commercialize them [4][8] - The collaboration is expected to leverage GSK's R&D expertise and global clinical network, accelerating the development of innovative therapies [5][6]

智通财经7月28日电，恒瑞医药公告，与GlaxoSmithKlineIntellectualProperty(No.3)Limited和 GlaxoSmithKlineIntellectualProperty(No.4)Limited公司（以下统称"GSK"）达成协议，将HRS-9821项目的 全球独家权利（不包括中国大陆、香港特别行政区、澳门特别行政区及台湾地区）和至多11个项目的全 球独家许可的独家选择权（不包括中国大陆、香港特别行政区、澳门特别行政区及台湾地区）有偿许可 给GSK。 恒瑞医药：将HRS-9821项目的全球独家权利和至多11个项目的全球独家许可的独家选择权有偿许可给 GSK ...

恒瑞医药公告，公司与GSK达成协议，将HRS-9821项目的全球独家权利和至多11个项目的全球独家许 可的独家选择权有偿许可给GSK。GSK将向恒瑞支付5亿美元的首付款，公司将有资格获得未来基于成 功开发、注册和销售里程碑付款的潜在总金额约120亿美元。 ...

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6]. Core Insights - Small nucleic acid drugs are expected to become the third major class of drugs after small molecules and antibodies, with unique advantages such as broad targets, strong specificity, high development efficiency, and long dosing intervals [9][38]. - The commercialization of rare diseases is maturing, and the long-term advantages for chronic diseases are becoming evident, with significant sales growth for products like Spinraza and Leqivo [9][60]. - There is a notable increase in business development (BD) activities, highlighting the potential of early-stage chronic disease pipelines [9]. Summary by Sections 1. Small Nucleic Acids: Potential as a New Drug Class - Small nucleic acid drugs, including ASO, siRNA, and Aptamer, interact with mRNA to regulate gene expression, offering a new technological pathway for drug development [13]. - The global market for small nucleic acid drugs has grown from $1.04 billion in 2017 to $5.09 billion in 2024, with a CAGR of 25.5% [60]. 2. Milestones in Overseas and Domestic Markets - In the overseas market, significant developments are expected in the TTR field and cardiovascular diseases, with drugs like Vutrisiran and Pelacarsen showing promise [9]. - In China, new therapies for chronic hepatitis B and competitive advancements in cardiovascular drugs are emerging, with several companies making progress in their pipelines [9][60]. 3. Investment Recommendations and Targets - The report suggests focusing on high-quality domestic companies involved in the development of small nucleic acid drugs targeting chronic hepatitis B and cardiovascular diseases, such as HengRui Medicine, China National Pharmaceutical Group, and others [9].

GSK (GSK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on July 30, might help the stock move higher if these key numbers are better than expectations. On the ...

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of GSK plc investors regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1]. Group 1: Company Developments - On July 17, 2025, GSK announced that the FDA Oncologic Drugs Advisory Committee voted against the overall benefit/risk profile for the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations [3]. - Following this announcement, GSK's American Depositary Receipt (ADR) price decreased by $1.81 per share, representing a 4.73% decline, closing at $36.47 per share on the same day [3]. Group 2: Legal Context - The Pomerantz Firm, known for its expertise in corporate, securities, and antitrust class litigation, is leading the investigation into GSK's practices [4]. - The firm has a long history of fighting for the rights of victims of securities fraud and has successfully recovered multimillion-dollar damages for class members [4].

Group 1 - Nearly 70 UK companies have established operations in Shanghai's Lingang area, covering industries such as pharmaceuticals, finance, and high-end manufacturing [1][3] - The Lingang New Area is viewed as a "testing ground" for institutional opening, with a policy framework promoting the free flow of investment, trade, capital, personnel, and data [3] - The area is accelerating the formation of world-class industrial clusters in integrated circuits, smart vehicles, and biomedicine, attracting major companies like Tesla, Boeing, and GSK [3][7] Group 2 - The UK-China Business Council emphasizes the complementary nature of industries between the two countries, particularly in digital economy, biomedicine, and new energy [3] - The 48 Group Club, a key player in UK-China trade relations, highlights the historical cooperation since 1953 and the potential for future collaboration [4][5] - UK companies are increasingly interested in Lingang as a gateway to China, with many planning visits and participation in events like the International Robot Expo [7][8] Group 3 - GSK has established a wholly-owned subsidiary in Lingang, operating core products through a contract manufacturing organization model [7] - Haleon, another UK pharmaceutical company, is leveraging Lingang's industrial cluster advantages to localize its operations across the entire supply chain [7] - Boeing is relocating its maintenance facility to Lingang, reflecting the area's favorable business environment and government support for high-end manufacturing [7]

Core Viewpoint - GSK's Blenrep combination therapy has been voted against by the FDA's Oncologic Drugs Advisory Committee (ODAC) due to an unfavorable benefit/risk profile, indicating that the risks currently outweigh the benefits for treating relapsed or refractory multiple myeloma [1][8]. GSK's Stock Performance - Following the ODAC announcement, GSK's shares fell by 4.7% [2]. - Year-to-date, GSK's shares have increased by 7.8%, contrasting with a 0.6% decline in the industry [6]. Regulatory Context - The ODAC's opinion is significant as the FDA typically considers it in their final decision, which is expected on July 23 [3][8]. - The Blenrep combination therapy has already been approved in the UK and Japan but faces regulatory challenges in the United States [8][11]. - Regulatory applications for the Blenrep combination are under review in the EU and other countries [9]. Clinical Study Background - The biologics license application (BLA) for the Blenrep combination was based on data from the III DREAMM-7 and DREAMM-8 studies, which met their primary endpoints of progression-free survival (PFS) [7]. - However, Blenrep was previously withdrawn from the U.S. market after failing to meet the primary endpoint in the phase III DREAMM-3 study [10].